A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Clinical trial NCT02151526 · COMPLETED

Trial details

NCT number: NCT02151526
Sponsor: Genetix Biotherapeutics Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Beta-Thalassemia Major Sickle Cell Disease

Start date: 2013-06-07
Primary completion: 2019-02-26
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.